Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Net Income (2016 - 2025)

Historic Net Income for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$27.4 million.

  • Myriad Genetics' Net Income fell 2398.19% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 24525.86%. This contributed to the annual value of -$127.3 million for FY2024, which is 5165.21% up from last year.
  • Per Myriad Genetics' latest filing, its Net Income stood at -$27.4 million for Q3 2025, which was down 2398.19% from -$330.5 million recorded in Q2 2025.
  • Myriad Genetics' Net Income's 5-year high stood at $24.6 million during Q3 2021, with a 5-year trough of -$330.5 million in Q2 2025.
  • Moreover, its 5-year median value for Net Income was -$31.2 million (2023), whereas its average is -$46.7 million.
  • In the last 5 years, Myriad Genetics' Net Income surged by 26184.21% in 2021 and then crashed by 80054.5% in 2025.
  • Myriad Genetics' Net Income (Quarter) stood at -$7.6 million in 2021, then tumbled by 456.58% to -$42.3 million in 2022, then increased by 26.24% to -$31.2 million in 2023, then plummeted by 36.22% to -$42.5 million in 2024, then surged by 35.53% to -$27.4 million in 2025.
  • Its Net Income was -$27.4 million in Q3 2025, compared to -$330.5 million in Q2 2025 and -$100000.0 in Q1 2025.